Y-mabs enters clinic with new cancer candidate
In a first for the firm, Y-mabs has leveraged its new SADA platform to develop a drug heading into testing against multiple cancer targets.
by christian bundgaard, translated by daniel pedersen
Danish-American biotech firm Y-mabs has gotten the nod from the US Food and Drug Administration (FDA) for a phase I trial with cancer candidate GD2-SADA, according to a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orion enters partnership with MSD, upgrades guidance
For subscribers
Evaxion Biotech's lung cancer candidate ready for clinic
For subscribers
